J&J re­ceives fifth FDA nod for treat­ing mul­ti­ple myelo­ma, with boxed warn­ing and REMS in tow

John­son & John­son’s Janssen has re­ceived its fifth drug ap­proval for mul­ti­ple myelo­ma, se­cur­ing an ac­cel­er­at­ed nod for its bis­pe­cif­ic Talvey on Thurs­day morn­ing.

The FDA cleared the an­ti­body, known in­ves­ti­ga­tion­al­ly as tal­que­tam­ab, for adults with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma af­ter four or more pri­or treat­ment at­tempts. Talvey will be­come avail­able with­in three weeks, a spokesper­son told End­points News via email. The list price is $45,000 per month or a range of $270,000 to $360,000, de­pend­ing on treat­ment du­ra­tion. In clin­i­cal stud­ies, pa­tients were typ­i­cal­ly on treat­ment for about six to eight months, the spokesper­son said, not­ing J&J ex­pects Medicare and most com­mer­cial in­sur­ance plans to cov­er Talvey.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER